A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Completed
ArQule
Phase 2
This is a randomized, placebo-controlled, double blind phase 2 study designed to compare
treatment with ARQ 197 plus erlotinib to erlotinib plus placebo in patients with non-small
cell lung cancer. The study will enroll patients who have had one prior chemotherapy regimen
(other than erlotinib) for NSCLC.
A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Completed
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
Phase 2
This is a randomized, placebo-controlled, double blind phase 2 study designed to compare
treatment with ARQ 197 plus erlotinib to erlotinib plus placebo in patients with non-small
cell lung cancer. The study will enroll patients who have had one prior chemotherapy regimen
(other than erlotinib) for NSCLC.
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
Completed
ArQule
Phase 2
This is a global randomized, placebo-controlled, double-blinded Phase 2 study designed to
compare treatment of ARQ 197 versus placebo in patients with unresectable HCC who had
radiographic disease progression after systemic first line therapy or were unable to tolerate
the therapy.
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
Completed
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
Phase 2
This is a global randomized, placebo-controlled, double-blinded Phase 2 study designed to
compare treatment of ARQ 197 versus placebo in patients with unresectable HCC who had
radiographic disease progression after systemic first line therapy or were unable to tolerate
the therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.